Literature DB >> 16924437

[Cutaneous lymphomas: classification and stage-adjusted therapy].

R Stadler1.   

Abstract

Cutaneous lymphomas are a heterogeneous group of clonal proliferations of T and B lymphocytes with various clinical manifestations and prognosis. The new EORTC WHO classification of cutaneous T- and B-cell lymphomas provides a uniform nomenclature based on clinical, histologic, cytologic and molecular biological features. Accurate classification is a prerequisite for uniform therapeutic concepts. For office-based dermatologist, more than 50% of the therapies deal with classic forms of cutaneous T-cell lymphomas, type mycosis fungoides. In recent years the paradigm for the therapy of cutaneous T-cell lymphomas has changed. Since early aggressive treatment with cytostatic agents does not increase the response rate or overall survival, a commonly accepted stage-adapted therapy is recommended. In this review the current status of the therapy of cutaneous lymphoma is described in detail.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924437     DOI: 10.1007/s00105-006-1189-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  28 in total

Review 1.  Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas.

Authors:  Eric C Vonderheid; Maria Grazia Bernengo; Günter Burg; Madeleine Duvic; Peter Heald; Liliane Laroche; Elise Olsen; Mark Pittelkow; Robin Russell-Jones; Masahiro Takigawa; Rein Willemze
Journal:  J Am Acad Dermatol       Date:  2002-01       Impact factor: 11.527

Review 2.  Interferons in dermatology. Present-day standard.

Authors:  R Stadler
Journal:  Dermatol Clin       Date:  1998-04       Impact factor: 3.478

3.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Authors:  E Olsen; M Duvic; A Frankel; Y Kim; A Martin; E Vonderheid; B Jegasothy; G Wood; M Gordon; P Heald; A Oseroff; L Pinter-Brown; G Bowen; T Kuzel; D Fivenson; F Foss; M Glode; A Molina; E Knobler; S Stewart; K Cooper; S Stevens; F Craig; J Reuben; P Bacha; J Nichols
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

4.  Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.

Authors:  Christiane Querfeld; Steven T Rosen; Timothy M Kuzel; Katharine A Kirby; Henry H Roenigk; Bettina M Prinz; Joan Guitart
Journal:  Arch Dermatol       Date:  2005-03

5.  Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.

Authors:  R L Piekarz; R Robey; V Sandor; S Bakke; W H Wilson; L Dahmoush; D M Kingma; M L Turner; R Altemus; S E Bates
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

6.  Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

Authors:  M Duvic; K Hymes; P Heald; D Breneman; A G Martin; P Myskowski; C Crowley; R C Yocum
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

7.  The evolving role of alemtuzumab in management of patients with CLL.

Authors:  S Faderl; S Coutré; J C Byrd; C Dearden; A Denes; M J S Dyer; S A Gregory; J G Gribben; P Hillmen; M Keating; S Rosen; P Venugopal; K Rai
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

Review 8.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

Review 9.  Therapy of cutaneous lymphoma--current practice and future developments.

Authors:  R Dummer; W Kempf; M Hess Schmid; A Häffner; G Burg
Journal:  Onkologie       Date:  2003-08

Review 10.  Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids.

Authors:  Rudolf Stadler; Almut Kremer
Journal:  Semin Oncol       Date:  2006-02       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.